Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia

NCT03237065 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

122

Enrollment

INDUSTRY

Sponsor class

Conditions

Iron Deficiency Anaemia
Iron Deficiency Anemia

Interventions

DRUG: Iron isomaltoside/ferric derisomaltose
DRUG: Ferric carboxymaltose

Sponsor

Pharmacosmos A/S